Recent from talks
Pluri Inc.
Knowledge base stats:
Talk channels stats:
Members stats:
Pluri Inc.
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
Pluristem was founded in 2001 by Shai Meretzki of the Technion, who made use of a stem cell patent which was developed during his Ph.D. studies at The Rappaport Faculty Of Medicine, Technion, under the supervision of Dr. Shosh Merchav, together with Professors Dov Zipori and Avinoam Kadouri from the Weizmann Institute of Science.
In 2003, the NASDAQ-listed shell company A1 Software acquired all shares and patents belonging to Pluristem and changed its name to Pluristem Life Systems. In 2007 the name was changed again, this time to Pluristem Therapeutics Inc. Pluristem's shares are traded on the NASDAQ exchange and the Tel Aviv Stock Exchange, as well as on the Frankfurt Stock Exchange.
In December 2020, the Genesis Prize and Start-up Nation Central named Pluri as one of the winners in a competition among Israeli high-tech and biotechnology companies.
In July 2022, the company changed its name from Pluristem Therapeutics to Pluri Inc. and its ticker symbol to PLUR from PSTI.
Pluristem is in the process of clinically testing the use of its PLX (PLacental eXpanded) cells in Phase I, Phase II and Phase III trials. A Phase III trial of PLX-(PAD)-peripheral arterial disease cells in the treatment of critical limb ischemia has been cleared to start enrolling patients by the U.S. Food and Drug Administration. The Phase III trial has also been cleared by regulators in Germany and the United Kingdom. Pluristem has completed enrollment of 172 patients in January 2017 for a multinational Phase II clinical trial of its PLX-PAD treatment pertaining to intermittent claudication. Results from the study suggest that PLX-R18 is safe and may significantly improve outcomes after bone marrow failure or hematopoietic cell transplantation. The U.S. Food and Drug Administration has also cleared Pluristem to commence patient enrollment in a Phase I trial of its PLX-R18 cells to treat insufficient hematopoietic recovery following bone marrow transplant.
PLX-R18 were initially developed with Professor Raphael Gorodetsky at Hadassah Hospital for the treatment of acute radiation syndrome and enhancement of bone marrow regeneration. The U.S. National Institutes of Health is currently evaluating Pluristem's PLX-R18 cells as a treatment for acute radiation syndrome. The dose finding portion of the study was successfully concluded and data showed that PLX-R18 treated subjects had an 85% survival rate compared to the placebo group which had a 50% survival rate. PLX-R18 can serve as a tool for governments to protect their citizens against potential exposure to nuclear radiation.
In May 2012, Pluristem reported that its experimental PLacental eXpanded cells were injected into the muscles of a 7-year-old Romanian girl undergoing treatment for bone marrow aplasia disease at the Hadassah Medical Center in Jerusalem. The girl had undergone two allogenic stem cell transplants since being admitted in August 2011, both of which failed to improve her condition. Two months thereafter, with the patient's condition deteriorating rapidly, the Director of Bone Marrow Transplantation, Cell Therapy and Transplantation Research Center at Hadassah felt that all available options had been exhausted and turned to Pluristem's PLX cells. The Helsinki committee at Israel's Ministry of Health approved the procedure under compassionate use. According to Pluristem CEO Zami Aberman, it was the first time ever that stem cells were injected into the muscle rather than into the body's blood system. Pluristem announced that the treatment led to a significant increase in the girl's red cells, white cells and platelets, effecting a reverse in her condition. She was released from the hospital soon after Pluristem's announcement.
Hub AI
Pluri Inc. AI simulator
(@Pluri Inc._simulator)
Pluri Inc.
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
Pluristem was founded in 2001 by Shai Meretzki of the Technion, who made use of a stem cell patent which was developed during his Ph.D. studies at The Rappaport Faculty Of Medicine, Technion, under the supervision of Dr. Shosh Merchav, together with Professors Dov Zipori and Avinoam Kadouri from the Weizmann Institute of Science.
In 2003, the NASDAQ-listed shell company A1 Software acquired all shares and patents belonging to Pluristem and changed its name to Pluristem Life Systems. In 2007 the name was changed again, this time to Pluristem Therapeutics Inc. Pluristem's shares are traded on the NASDAQ exchange and the Tel Aviv Stock Exchange, as well as on the Frankfurt Stock Exchange.
In December 2020, the Genesis Prize and Start-up Nation Central named Pluri as one of the winners in a competition among Israeli high-tech and biotechnology companies.
In July 2022, the company changed its name from Pluristem Therapeutics to Pluri Inc. and its ticker symbol to PLUR from PSTI.
Pluristem is in the process of clinically testing the use of its PLX (PLacental eXpanded) cells in Phase I, Phase II and Phase III trials. A Phase III trial of PLX-(PAD)-peripheral arterial disease cells in the treatment of critical limb ischemia has been cleared to start enrolling patients by the U.S. Food and Drug Administration. The Phase III trial has also been cleared by regulators in Germany and the United Kingdom. Pluristem has completed enrollment of 172 patients in January 2017 for a multinational Phase II clinical trial of its PLX-PAD treatment pertaining to intermittent claudication. Results from the study suggest that PLX-R18 is safe and may significantly improve outcomes after bone marrow failure or hematopoietic cell transplantation. The U.S. Food and Drug Administration has also cleared Pluristem to commence patient enrollment in a Phase I trial of its PLX-R18 cells to treat insufficient hematopoietic recovery following bone marrow transplant.
PLX-R18 were initially developed with Professor Raphael Gorodetsky at Hadassah Hospital for the treatment of acute radiation syndrome and enhancement of bone marrow regeneration. The U.S. National Institutes of Health is currently evaluating Pluristem's PLX-R18 cells as a treatment for acute radiation syndrome. The dose finding portion of the study was successfully concluded and data showed that PLX-R18 treated subjects had an 85% survival rate compared to the placebo group which had a 50% survival rate. PLX-R18 can serve as a tool for governments to protect their citizens against potential exposure to nuclear radiation.
In May 2012, Pluristem reported that its experimental PLacental eXpanded cells were injected into the muscles of a 7-year-old Romanian girl undergoing treatment for bone marrow aplasia disease at the Hadassah Medical Center in Jerusalem. The girl had undergone two allogenic stem cell transplants since being admitted in August 2011, both of which failed to improve her condition. Two months thereafter, with the patient's condition deteriorating rapidly, the Director of Bone Marrow Transplantation, Cell Therapy and Transplantation Research Center at Hadassah felt that all available options had been exhausted and turned to Pluristem's PLX cells. The Helsinki committee at Israel's Ministry of Health approved the procedure under compassionate use. According to Pluristem CEO Zami Aberman, it was the first time ever that stem cells were injected into the muscle rather than into the body's blood system. Pluristem announced that the treatment led to a significant increase in the girl's red cells, white cells and platelets, effecting a reverse in her condition. She was released from the hospital soon after Pluristem's announcement.